GLP-1 rebound weight gain: what the evidence actually shows

What did @awenotv actually say?

Honestly, this is a difficult video to fact-check, and not because the science is complicated. The transcript is largely incoherent. There are no clear, verifiable claims about GLP-1 medications, rebound weight gain, or health risks. The caption promises "el efecto rebote y los riesgos para la salud" (the rebound effect and health risks), but the spoken content never delivers that discussion in any intelligible form.

What we can do is use the caption's stated topic as a starting point, because rebound weight after stopping GLP-1 medications is a real and significant clinical issue that deserves an honest look.

Does the science back up the rebound concern?

Yes, and it is more pronounced than most social media coverage suggests. The rebound effect after stopping GLP-1 receptor agonists is well-documented, not hypothetical. In the STEP 4 trial (Wilding et al., 2022, New England Journal of Medicine), participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight within one year. Their cardiometabolic improvements also largely reversed.

A similar pattern appeared with tirzepatide. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) found that participants switching from tirzepatide to placebo regained an average of 14 percentage points of body weight over 52 weeks, compared to continued loss in the group that stayed on the drug.

• Rebound is not caused by willpower failure. It reflects hormonal and metabolic adaptations that persist after discontinuation.
• Appetite-regulating hormones like ghrelin tend to rebound after weight loss, and GLP-1 medications suppress this. Remove the drug, and hunger signals return aggressively.
• The evidence suggests these medications may need to be continued long-term for sustained effect, similar to how antihypertensives are managed.

What did they get wrong (or right)?

There is no coherent claim in this video to evaluate as right or wrong. That is itself a problem worth naming. Videos with alarming captions about drug risks that then deliver no actual information are doing something arguably worse than spreading misinformation: they generate anxiety without education.

The caption framing around "risks" is not inherently wrong. There are real risks worth discussing. Gastrointestinal side effects affect a significant portion of users. Muscle mass loss during rapid weight reduction is a documented concern (Wilding, 2021, Obesity Reviews). Rare but serious risks like pancreatitis and medullary thyroid carcinoma carry FDA label warnings.

But none of this was said in the video. If the creator intended to inform their 9,800 viewers about GLP-1 risks, the execution failed completely.

What should you actually know?

If you are using or considering a GLP-1 medication, the rebound question deserves a real conversation with a clinician, not a TikTok video. Here is what the evidence actually supports:

• Weight regain after stopping is common and biologically driven, not a character flaw.
• Discontinuation should be planned, not abrupt, and ideally supervised by a provider familiar with metabolic medicine.
• Lifestyle changes in nutrition and activity do attenuate rebound, but rarely eliminate it entirely without the medication (Garvey et al., 2023, Nature Medicine).
• Compounded versions of semaglutide or tirzepatide are not equivalent to FDA-approved branded drugs. Formulation, dosing accuracy, and sterility standards differ. Do not assume interchangeability.

The rebound effect is real. It is one of the strongest arguments for treating obesity as a chronic condition requiring ongoing management, not a short-term fix. Any platform or creator discussing this topic owes their audience that framing.